Objective To investigate the efficacy and safety of insulin glargine in combination with sitagliptin on elderly patients with type 2 diabetes. Methods 78 patients ( > 60 year-old ) were randomly divided into two groups:insulin glargine/sitagliptin combination group( n =40,group G )and biosynthesis premixed 30/70 insulin group ( n =38,group N ). The dose was adjusted according to blood glucose,the fasting glucose,2 h postprandial blood glucose ,glycosylated hemoglobin( HbA1C ),the incidence of hypoglycemia and body mass index( BMI )after 12 weeks of treatment of the two groups were compared. Results 2 h postprandial blood glucose and the incidence of hypoglycemi-a in group G were less than those in group N( P 0. 05 ). Conclusion The treatment of insulin glargine in combination with sitagliptin is safe, effective and convenient for elderly patients with type 2 diabetes. This treatment program with a small incidence of hypoglycemia is very suitable for old patients with type 2 diabetes complicated with poor cognitive activities inconvenient, poor eyesight or a variety of chronic diseases.%目的 探讨甘精胰岛素联用西格列汀治疗高龄2型糖尿病的疗效及安全性.方法 将78例60岁以上的2型糖尿病患者随机分成甘精胰岛素联用西格列汀组(G组)40例和生物合成预混30/70人胰岛素组(N组)38例,根据血糖情况调整用药剂量,治疗12周后比较两组的空腹血糖、餐后2 h血糖、糖化血红蛋白(HbA1c)、低血糖发生率及体重指数(BMI).结果 G组在空腹2 h血糖和低血糖发生率方面均低于N组,两组比较差异有统计学意义(P＜0.05);在餐后血糖、HbA1c和BMI方面两组比较差异无统计学意义(P＞0.05).结论 甘精胰岛素与西格列汀联用对老年2型糖尿病患者是一种安全、有效且方便的治疗方案,低血糖发生率低,尤其是对认知力较差、活动不方便、视力差或合并多种慢性病的高龄2型糖尿病患者尤为适用.
展开▼
